BLACK FRIDAY SPECIAL

25% OFF + 1-Yr NT Prime FREE !

Use
00h : 00m : 00s
Claim→
logo
Market statusData NSENot investment advice
SYNGENE INTERNATIONAL

SYNGENE INTERNATIONAL Latest Share Price (SYNGENE)

₹451.70
14.35+3.28%
Overall Score50/100
Day range434
₹451.70
456
52-week344
₹451.70
679
Above low+31.1%
Below high33.5%
Range position32%
Open437.30
Prev Close437.35
Bid451.681.0K
Ask451.72639

TODAY IN ONE LINE

SYNGENE jumped 3.3% on above-average volume (3.1x avg), outperforming Nifty's 1.1% move, with no exchange filing today, suggesting a market-driven move.

With a market cap of ₹18,268.05 Cr., it trades at a P/E of 97.95. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.

Volume2.6M−6%vs 20D avg
Price Band20
Lower Band301.2
Upper Band451.7
Tick Size0.05
Daily Volatility2.04%
Annualised Vol38.97%
Market Cap₹18,268.05 Cr.
Promoter52.59%
Face Value₹10
Fwd P/E34.66
PEG7.31
EV/EBITDA22.23
P/S4.46
ROA4.75%
Beta0.74
Div Payout31.81%
THE STOCK SCORE
Overall Score50/100
Updated 07 Nov

How good is this company?

Overall performance across 5 key dimensions.

Each card tappable → shows formula + inputs
FLAGS & NEWS

SYNGENE INTERNATIONAL flags & news 

Key strengths, potential risks, and recent updates.

✅ 5 green flags🚩 5 red flags

Green Flags

  • ●Quarterly OutperformanceLatest quarter Sales up 13.1% and Profit up 457.8%
  • ●High Promoter HoldingPromoters hold 52.6% skin-in-the-game
  • ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
  • ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
  • ●Zero Pledge RiskNo recent active promoter pledging found

Red Flags

  • ●Earnings DeclineEPS (TTM) has contracted by 19.5% YoY
  • ●Poor Capital ReturnsLow ROE of 6.5%
  • ●Expensive ValuationTrading at a high P/E ratio of 55.0x
  • ●FII SellingFII holding decreased by 1.68% QoQ
  • ●Rising Receivables vs SalesReceivables grew 17.4% outpacing sales growth of 4.4%

Latest SYNGENE INTERNATIONAL News

THE CHANGELOG

What changed recently?

Recent events, corporate actions, and announcements.

16 NOV 2026
corporate
Analysts/Institutional Investor Meet/Con. Call Updates - Syngene International Limited has informed the Exchange about Schedule of meet
View PDF
🔒Prime: full history + alerts on this stock
Valuation

SYNGENE INTERNATIONAL valuation: P/E, P/B and sector benchmarks.

Twelve years of multiples investors have paid for SYNGENE INTERNATIONAL, framed against the sector median so the premium or discount is obvious at a glance.

SYNGENE INTERNATIONAL trades at a P/E of 97.95× and P/B of 3.75×, against the Healthcare sector median P/E of 49.50×.

Key MetricsMarket + reported · 20 Nov 2026Consolidated

Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.

Valuation

Valuation

Market Cap
₹18,268.05 Cr.
P/E Ratio
97.95
P/B Ratio
3.75
EPS
₹0.8
Profitability

Profitability

ROE
6.48%
ROCE
6.92%
Net Margin
11.26%
Op Margin
12.3%
Growth

Growth

EPS YoY
-19.5%
Revenue YoY
1.8%
Qtr Sales
13.14%
Qtr Profit
457.78%
Financial Health

Financial Health

Debt / Equity
—
Book Value
₹119.88
Div Yield
0.28%
Promoter Holding
52.59%
Technicals

SYNGENE INTERNATIONAL technical analysis: indicators, pivots and CPR.

Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for SYNGENE INTERNATIONAL — derived from the latest tape, not yesterday's close.

SYNGENE INTERNATIONAL last traded at ₹451.7 with an intraday range of ₹434.05–₹456 — latest indicator, pivot and CPR signals below.

Last updated: 23 November 2026, 4:08 pm IST

Pivot points

Standard pivot — most widely referenced.

Pivot levels · Classic

Last: ₹451.70
LevelPrice (₹)Distance% Δ
R4504.35+52.65+11.66%
R3482.40+30.70+6.80%
R2469.20+17.50+3.87%
R1460.45+8.75+1.94%
PIVOT447.25-4.45-0.99%
CURRENT451.70——
S1438.50-13.20-2.92%
S2425.30-26.40-5.84%
S3416.55-35.15-7.78%
S4394.60-57.10-12.64%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: 445.02P: 447.25TC: 449.48
R1
R2
R3
R4
indicator
LTP: 451.70
PDH: 438.95
PDL: 430.15
● Market Sentiment

SYNGENE is trading Above CPR, indicating Bullishness

● CPR Width

CPR is Wider, suggesting unlikely for trending moves

● Opening Range

Day's range: ₹434.05–₹441.85

● Price Position

Trading Above opening range, showing Bullishness

Financials

SYNGENE INTERNATIONAL financials: P&L, balance sheet, cash flow, ratios.

Reported annual and quarterly results for SYNGENE INTERNATIONAL — consolidated or standalone — with margins, YoY growth and key ratios inline.

SYNGENE INTERNATIONAL reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹18,268.05 Cr. and reported EPS of ₹0.80.

iTap any row for a plain-English meaning▲▼Change vs a year ago — green means the move is healthy for that line, red means it isn’tDerivedCalculated by us, not reported directly
Mobile view
Latest vs previous year
MetricMar 2026Apr 2026
Revenue from Operations3,739
3,739
▲ 0.0%
Sales Growth YoY %Derived2.64%
2.64%
Other Income71
71
▲ 0.0%
Total Income3,809
3,809
▲ 0.0%
919
919
▲ 0.0%
Gross ProfitDerived2,820
2,820
▲ 0.0%
Gross Margin %Derived75.43%
75.43%
1,902
1,902
▲ 0.0%
EBITDA (Operating Profit)Derived919
919
▲ 0.0%
OPM %Derived24.57%
24.57%
425
425
▲ 0.0%
Profit Before Tax (PBT)411
411
▲ 0.0%
94
94
▲ 0.0%
Effective Tax %Derived22.93%
22.93%
Total Profit for Period317
317
▲ 0.0%
Net Profit (Owner's PAT)Derived317
317
▲ 0.0%
Net Profit Margin %Derived8.47%
8.47%
PAT Growth YoY %Derived-36.17%
-36.17%
Earnings Per Share (EPS ₹)7.86
7.86
▲ 0.0%
Diluted Shares Outstanding (Cr)40
40
▲ 0.0%
Other Comprehensive Income (Net of Tax)-196
-196
▲ 0.0%
Total Expenses (incl. D&A & Interest)3,399
3,399
▲ 0.0%
Material Cost % of RevenueDerived24.37%
24.37%
Employee Cost % of RevenueDerived29.55%
29.55%
Other Cost % of RevenueDerived21.31%
21.31%
Interest Coverage (x)Derived9.54x
9.54x
Sales CAGR · 3Y
+0.9%
Sales CAGR · 5Y
+1.4%
PAT CAGR · 3Y
-13.9%
PAT CAGR · 5Y
-9.1%
all values in ₹ Cr unless marked % / x / ₹ · fiscal-period end shown · reported figures via Stockezee financials API · annual results may be audited; quarterly results may be unaudited or limited-review
Segment Analysis

SYNGENE INTERNATIONAL segment analysis : revenue and profit mix.

Disclosed business segments at SYNGENE INTERNATIONAL with their share of revenue and profit, switchable between consolidated and standalone reporting.

SYNGENE INTERNATIONAL discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.

Segment-wise Financial Analysis

Thesis

The Bull, Bear, and Flip case for SYNGENE INTERNATIONAL.

Our AI distills the core fundamental drivers supporting SYNGENE INTERNATIONAL, the risks that threaten it, and the quantitative conditions that could weaken the thesis.

bull case

What you're getting.

No strengths or opportunities on record.

bear case

Key Risks.

No weaknesses or threats on record.

flip conditions

Flip Conditions.

  • Valuation risk. a P/E above 127 (~2.6× the sector multiple of 49.5) would leave less room for earnings disappointment.

  • Fundamental risk. a shrinking deal pipeline (TCV) or margins below historical averages would weaken the thesis.

  • Watch wage inflation and attrition rates — primary threats to operating leverage in IT.

  • Return-quality risk. ROE below 8% would indicate weaker capital compounding.

Shareholding

SYNGENE INTERNATIONAL shareholding pattern: promoters, FII, DII and public.

Quarter-on-quarter ownership shifts in SYNGENE INTERNATIONAL — who is buying, who is exiting, and which institutions hold the largest positions.

Shareholding Pattern

Annual • Sep 2026

DII29.30%↑1.28%
Public7.56%↑0.42%
FII10.14%↓1.68%
Promoters52.59%
Others0.41%↓0.02%

Ownership Distribution

Domestic Institutions
29.30%
Retail & Public
7.56%
Foreign Institutions
10.14%
Promoters
52.59%
Others
0.41%

Category Trends

Foreign Institutions Breakdown
Total Holding: 10.14%
Net Change: -1.68%
Category Total10.14%
Total Holding10.14%
Net Change-1.68%
Not Fully Disclosed

⚠️Partial Disclosure Notice

Individual institutions below total 1.16%, but category aggregate is 10.14%. Some institutions may not be disclosed by the company as per regulatory requirements.

Institution Name
Trend (Last 6)
Holding %
QoQ Change
YoY ChangePeriod
Government Of Singapore
1.16%
0.97%
-0.97%
Sep 2026
ABERDEEN STANDARD SICAV I - ASIAN SMALLER COMPANIE
0.00%
0.00%
0.00%
Sep 2026
Kotak Funds - India Midcap Fund
0.00%
0.00%
0.00%
Sep 2026
STEADVIEW CAPITAL MAURITIUS LIMITED
0.00%
0.00%
0.00%
Sep 2026
Gaoling Fund, L.P.
0.00%
0.00%
0.00%
Sep 2026
Government Pension Fund Global
0.00%
0.00%
0.00%
Sep 2026
THELEME MASTER FUND LIMITED
0.00%
0.00%
0.00%
Sep 2026
CAMAS INVESTMENTS PTE. LTD.
0.00%
0.00%
0.00%
Sep 2026
Silver Leaf Oak (Mauritius) Limited
0.00%
0.00%
0.00%
Sep 2026
GOVERNMENT OF SINGAPORE - E
0.00%
0.00%
0.00%
Sep 2026
Peers

SYNGENE INTERNATIONAL peer comparison — same-sector benchmarks.

Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — SYNGENE INTERNATIONAL is highlighted for quick read-across.

Quick Compare

Largest by Market Cap
SYNGENE INTERNATIONAL
₹18,268.05 Cr
Best Profit Growth
SYNGENE INTERNATIONAL
457.78 %
Highest Dividend Yield
VIMTA LABS
0.43 %
09 · Chart Patterns

SYNGENE INTERNATIONAL chart patterns: breakouts, tops and bottoms.

Auto-detected classical chart patterns for SYNGENE INTERNATIONAL — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.

Delivery Conviction

SYNGENE INTERNATIONAL delivery volume — last 20 sessions of conviction.

Daily traded volume and delivery percentage for SYNGENE INTERNATIONAL over 20 sessions — the gap between intraday flipping and genuine accumulation.

Latest session delivery in SYNGENE INTERNATIONAL stood at 44.2% of traded volume, against a 20-day average of 48.2%.

Avg Delivery (20D)48.2%-4.0 ppt latest vs avg
Highest Delivery79%on 16 Nov
Avg Volume (20D)27.09 L20-day run-rate
Conviction Trend↓ Weakening-4.0 ppt latest read
Volume & Delivery · last 20 sessions
Exchange Filings & Investor Updates

SYNGENE INTERNATIONAL announcements: results, concalls, ratings, M&A.

Filings SYNGENE INTERNATIONAL sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.

SYNGENE INTERNATIONAL files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 260 documents below.

  1. 16 Nov 2026Analysts/Institutional Investor Meet/Con. Call UpdatesView PDF

    Analysts/Institutional Investor Meet/Con. Call Updates

    Syngene International Limited has informed the Exchange about Schedule of meet

  2. 12 Nov 2026Analysts/Institutional Investor Meet/Con. Call UpdatesView PDF

    Analysts/Institutional Investor Meet/Con. Call Updates

    Syngene International Limited has informed the Exchange about Schedule of meet

  3. 02 Nov 2026Analysts/Institutional Investor Meet/Con. Call UpdatesView PDF

    Analysts/Institutional Investor Meet/Con. Call Updates

    Syngene International Limited has informed the Exchange about Transcript

  4. 29 Oct 2026Copy of Newspaper PublicationView PDF

    Copy of Newspaper Publication

    Syngene International Limited has informed the Exchange about Copy of Newspaper Publication

  5. 27 Oct 2026Investor PresentationView PDF

    Investor Presentation

    Syngene International Limited has informed the Exchange about Investor Presentation

Corporate Actions

SYNGENE INTERNATIONAL dividend history, splits and bonus issues.

Every dividend, stock split and bonus issue SYNGENE INTERNATIONAL has declared, sequenced by announce and record date.

SYNGENE INTERNATIONAL corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.

Insider Activity

SYNGENE INTERNATIONAL insider trading: promoter and management activity.

Promoter, director and designated-employee transactions in SYNGENE INTERNATIONAL as reported to SEBI — buying and selling signals from the people who know the business best.

SYNGENE INTERNATIONAL insider activity below tracks 3 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).

InsiderCategoryTxn DateActionQuantityValue (₹)Price
ANJAN CHAKRABARTIInsider27 Dec 2024sell−6.2 K₹52.65 L₹850.59
ANJAN CHAKRABARTIInsider20 Dec 2024sell−27.2 K₹2.29 Cr.₹843.54
ANJAN CHAKRABARTIInsider19 Dec 2024buy+58.4 K₹5.02 Cr.₹859.73
About the Company

About SYNGENE INTERNATIONAL: business, sector, key facts.

What SYNGENE INTERNATIONAL does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.

SYNGENE INTERNATIONAL operates in the Healthcare Research Analytics & Technology industry under the Healthcare sector, listed as NSE: SYNGENE, BSE: 539268.

SYNGENE
Healthcare

SYNGENE INTERNATIONAL

NSE · SYNGENE·BSE · 539268·www.syngeneintl.com

Syngene International Limited is a leading contract research and manufacturing organization (CRO/CMO) with a global presence, offering a comprehensive suite of services across the drug discovery and development value chain. Their services span diverse therapeutic areas and cater to a wide range of clients including pharmaceutical, biotechnology, animal health, and other industries. Their geographical reach extends to India, the United States, Europe, and other international markets, highlighting their established global network and capacity.

Syngene's services in drug discovery encompass a broad spectrum, from early-stage research to preclinical development. This includes expertise in discovery chemistry (synthetic and medicinal chemistry, library and peptide synthesis, etc.), discovery biology (recombinant DNA engineering, cell line development, and various other biological assays), and computational and analytical chemistry. They also provide lead generation services crucial for initiating drug development pipelines.

Beyond drug discovery, Syngene offers extensive development and manufacturing capabilities. Their services include chemical, formulation, analytical, and clinical development, along with commercial manufacturing and sterile fill-finish capabilities. This ensures a seamless transition from discovery to commercialization for their clients. They also provide crucial support services for clinical trials, including management, data management, bioanalysis, and regulatory support.

Syngene's capabilities extend beyond traditional small molecule therapeutics. They possess expertise in biologics, peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization technologies, showcasing their adaptability to emerging therapeutic modalities. Their integrated approach combining chemistry, biology, safety assessment, computational, and data sciences provides a holistic solution for clients seeking comprehensive drug development partnerships.

The company boasts significant collaborations with prominent pharmaceutical giants such as Bristol-Myers Squibb, Baxter Inc., and Amgen Inc., underscoring its reputation and the quality of services provided. Established in 1993 and headquartered in Bengaluru, India, Syngene is a subsidiary of Biocon Limited, benefiting from the parent company's experience and resources within the broader pharmaceutical landscape.

company facts
Employees—
SectorHealthcare
HeadquartersBengaluru, India
Market Cap₹18,268.05 Cr.
Listed OnNSE
leadership39 on record
Dr. Jayashree Aiyar
Chief Scientific Officer
Dr. Jayashree Aiyar Ph.D.
Chief Scientific Officer
Dr. Jayashree Aiyar Ph.D.
Chief Scientific Officer & Head of Discovery Services
Dr. Kenneth Barr
Senior Vice President - Research Services
Dr. Kiran Mazumdar Shaw
Non-Executive Chairman of the Board
Dr. Kiran Mazumdar-Shaw B.Sc (Hons), B.Sc.
Executive Chairperson
Dr. Kush Parmar
Non-Executive Independent Director
Dr. Vijay Kuchroo
Non-Executive Independent Director
Mr. Ajay Tandon
Head of Strategy & Corporate Development
Mr. Ajit Manocha
Head of IT
Mr. Alex Del Priore
Senior Vice President - Manufacturing Services
Mr. Alok Mehrotra
Chief Quality Officer
§ ∞ · Plainly Answered

Questions investors ask about SYNGENE INTERNATIONAL (SYNGENE).

Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.

01What is the current share price of SYNGENE INTERNATIONAL (SYNGENE)?

The current share price of SYNGENE INTERNATIONAL (SYNGENE) is ₹451.70. Today, the stock has gained by ₹14.35 (3.28%), trading in a range of ₹434.05 to ₹456.00. The stock opened at ₹437.30 with a trading volume of 25,57,651 shares.

02Is SYNGENE INTERNATIONAL stock a good investment for long-term?

SYNGENE INTERNATIONAL can be considered for long-term investment based on several factors. The company has a market capitalization of ₹18,268.05 Cr., P/E ratio of 97.95, ROE of 6.48%, and ROCE of 6.92%. The dividend yield stands at 0.28%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.

03What is the 52-week high and low price of SYNGENE INTERNATIONAL stock?

The 52-week high price of SYNGENE INTERNATIONAL (SYNGENE) is ₹678.95, while the 52-week low is ₹344.45. Currently trading at ₹451.70, the stock is 31.14% above its 52-week low and 33.47% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.

04Should I buy SYNGENE INTERNATIONAL stock at the current price?

Whether to buy SYNGENE INTERNATIONAL stock at ₹451.70 depends on multiple factors. The stock is currently trading with a P/E ratio of 97.95 and P/B ratio of 3.75. Today's performance shows a gain of 3.28%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.

05What is the dividend yield of SYNGENE INTERNATIONAL and when is the next dividend?

SYNGENE INTERNATIONAL offers a dividend yield of 0.28%, which means for every ₹100 invested at the current price of ₹451.70, you can expect to receive approximately ₹0.28 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.

06What are the key financial ratios and metrics of SYNGENE INTERNATIONAL?

SYNGENE INTERNATIONAL's key financial metrics include: P/E Ratio: 97.95, P/B Ratio: 3.75, ROE: 6.48%, ROCE: 6.92%, Dividend Yield: 0.28%, EPS: ₹0.80, Book Value: ₹119.88, and Debt-to-Equity: 0. The company's market cap stands at ₹18,268.05 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.

07How is SYNGENE INTERNATIONAL stock performing today in the market?

SYNGENE INTERNATIONAL stock opened at ₹437.30 and is currently trading at ₹451.70, showing a gain of ₹14.35 (3.28%). The intraday high is ₹456.00 and low is ₹434.05. The trading volume stands at 25,57,651 shares, indicating strong market participation today.

08What is the P/E ratio of SYNGENE INTERNATIONAL and what does it indicate?

SYNGENE INTERNATIONAL has a Price-to-Earnings (P/E) ratio of 97.95, which means investors are willing to pay 97.95 for every ₹1 of earnings. With an EPS of ₹0.80, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.

Disclaimer

The data, ratios and commentary about SYNGENE INTERNATIONAL (SYNGENE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.